• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[청년의사] [ESMO 2023] 국산 CAR-T 치료제 ‘안발셀’ 허가 청신호?

2023/10/25

[ESMO 2023] 국산 CAR-T 치료제 ‘안발셀’ 허가 청신호? < 산업 < 뉴스 < 기사본문 – 청년의사 (docdocdoc.co.kr)

청년의사 김찬혁 기자

Prev큐로셀, 2023 유럽종양학회에서 ‘최우수 포스터’ 선정
Next큐로셀, 차세대 CAR-T 임상2상 완료 “국내 최초 사례”
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.